Comparative Pharmacology
Head-to-head clinical analysis: ERYC 125 versus ERYPED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC 125 versus ERYPED.
ERYC 125 vs ERYPED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic